A prospective, randomized, placebo-controlled, double-blind, multicenter study of the effects of irbesartan on aortic dilatation in Marfan syndrome (AIMS trial): study protocol

BACKGROUND: Cardiovascular complications are the leading cause of mortality and morbidity in Marfan syndrome (MFS), a dominantly inherited disorder caused by mutations in the gene that encodes fibrillin-1. There are approximately 18,000 patients in the UK with MFS. Current treatment includes careful...

Descripción completa

Detalles Bibliográficos
Autores principales: Mullen, Michael J, Flather, Marcus D, Jin, Xu Yu, Newman, William G, Erdem, Guliz, Gaze, David, Valencia, Oswaldo, Banya, Winston, Foley, Claire E, Child, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220813/
https://www.ncbi.nlm.nih.gov/pubmed/24289736
http://dx.doi.org/10.1186/1745-6215-14-408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220813/
https://www.ncbi.nlm.nih.gov/pubmed/24289736
http://dx.doi.org/10.1186/1745-6215-14-408

Ejemplares similares